Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1861. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. 15351193 2004 09 07 2004 09 21 2015 06 16 1474-547X 364 9437 2004 Sep 4-10 Lancet (London, England) Lancet Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. 858-68 Findings from (...) the National Surgical Adjuvant Breast and Bowel Project B-14 and B-20 trials showed that tamoxifen benefited women with oestrogen-receptor-positive tumours and negative axillary nodes, and that chemotherapy plus tamoxifen was more effective than tamoxifen alone. We present long-term findings from those trials and relate them to age, menopausal status, and tumour oestrogen-receptor concentrations. We also discuss the extent of progress made in the treatment of such patients. B-14 patients were randomly

Lancet2004

1862. Risk for distant recurrence of breast cancer detected by mammography screening or other methods.

Risk for distant recurrence of breast cancer detected by mammography screening or other methods. CONTEXT: Selection of systemic adjuvant therapies for women diagnosed as having breast cancer is based on risk estimations for cancer recurrence. In such estimations, tumors detected by mammography screening are considered to be associated with a similar risk of recurrence as tumors of similar size found by other methods. OBJECTIVE: To compare the risk of recurrence and survival among women (...) with cancerous tumors detected by mammography screening compared with other methods (outside of screening). DESIGN, SETTING, AND PATIENTS: Retrospective study comparing clinical, histopathological, and biological features of cancerous tumors detected by mammography screening compared with tumors detected outside of screening. Women diagnosed as having breast cancer in 1991 or 1992 were identified from the Finnish Cancer Registry (n = 2842). The median follow-up time was 9.5 years. Cancer biological variables

JAMA2004

1863. Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Circulating tumor cells, disease progression, and survival in metastatic breast cancer. BACKGROUND: We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer. METHODS: In a prospective, multicenter study, we tested 177 patients with measurable metastatic breast cancer for levels of circulating tumor cells both before the patients were to start a new line of treatment and at the first follow-up visit. The progression of the disease (...) from therapy. The multivariate Cox proportional-hazards regression showed that, of all the variables in the statistical model, the levels of circulating tumor cells at baseline and at the first follow-up visit were the most significant predictors of progression-free and overall survival. CONCLUSIONS: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer. Copyright 2004

NEJM2004

1864. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. BACKGROUND: The value of regular surveillance for breast cancer in women with a genetic or familial predisposition to breast cancer is currently unproven. We compared the efficacy of magnetic resonance imaging (MRI) with that of mammography for screening in this group of high-risk women. METHODS: Women who had a cumulative lifetime risk of breast cancer of 15 percent or more were (...) screened every six months with a clinical breast examination and once a year by mammography and MRI, with independent readings. The characteristics of the cancers that were detected were compared with the characteristics of those in two different age-matched control groups. RESULTS: We screened 1909 eligible women, including 358 carriers of germ-line mutations. Within a median follow-up period of 2.9 years, 51 tumors (44 invasive cancers, 6 ductal carcinomas in situ, and 1 lymphoma) and 1 lobular

NEJM2004

1865. Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women

Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women Article Text Therapeutics Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women Free Edmond

Evidence-Based Medicine (Requires free registration)2004

1866. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk.

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. CONTEXT: Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a decrease in the risk of several cancers, including breast cancer. NSAIDs inhibit cyclooxygenase activity and thereby reduce prostaglandin synthesis; prostaglandins stimulate aromatase gene expression and thereby stimulate estrogen biosynthesis. Given the importance of estrogen (...) in the pathogenesis of breast cancer, the ability of aspirin and other NSAIDs to protect against breast cancer could vary according to hormone receptor status. OBJECTIVES: To determine the association between the frequency and duration of use of aspirin and other NSAIDs and breast cancer risk and to investigate whether any observed association is more pronounced for women with hormone receptor-positive breast cancers. DESIGN, SETTING, AND PATIENTS: Population-based case-control study of women with breast cancer

JAMA2004

1867. HER-2 testing in breast cancer using parallel tissue-based methods.

HER-2 testing in breast cancer using parallel tissue-based methods. CONTEXT: Testing for HER-2 oncogene in breast cancer has increased because of its role as a prognostic and predictive factor. Some advocate gene testing by fluorescence in situ hybridization (FISH) vs protein testing by immunohistochemistry as the method which most accurately evaluates and predicts response to the anti-HER-2 antibody, trastuzumab. However, critical examination of FISH on a screening basis has yet (...) from 2963 patients (median age, 56 years) with breast cancer received from 135 hospitals and cancer centers in 29 states, was performed at a reference laboratory from January 1, 1999, to May 15, 2003. Every specimen evaluated by FISH was parallel tested with immunohistochemistry tests. MAIN OUTCOME MEASURES: With FISH as the presumed standard testing method, the positive and negative predictive values and sensitivity and specificity of immunohistochemistry were calculated. RESULTS: A total of 3260

JAMA2004

1868. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study.

Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. OBJECTIVE: To determine whether any increase in the incidence of breast cancer in women detected by mammography is compensated for by a drop in the incidence after age 69, years when women are no longer invited for screening. DESIGN: Population based cohort study of incidence of breast cancer during the introduction of nationwide screening programmes. SETTING: Norway and Sweden (...) . PARTICIPANTS: All women aged above 30 years (1.4 and 2.9 million, respectively, in 2000). MAIN OUTCOME MEASURES: Changes in age specific incidence rates of invasive breast cancer associated with the introduction of the screening programmes. RESULTS: As a result of screening the recorded incidence of breast cancer in women aged 50-69 years increased by 54% in Norway and 45% in Sweden. There was no corresponding decline in incidence after the age of 69 years. CONCLUSIONS: Without screening one third of all

BMJ2004 Full Text: Link to full Text with Trip Pro

1869. Doctors' communication of trust, care, and respect in breast cancer: qualitative study.

Doctors' communication of trust, care, and respect in breast cancer: qualitative study. OBJECTIVE: To determine how patients with breast cancer want their doctors to communicate with them. DESIGN: Qualitative study. SETTING: Breast unit and patients' homes. PARTICIPANTS: 39 women with breast cancer. MAIN OUTCOME MEASURE: Patients' reports of doctors' characteristics or behaviour that they valued or deprecated. RESULTS: Patients were not primarily concerned with doctors' communication skills (...) . Instead they emphasised doctors' enduring characteristics. Specifically, they valued doctors whom they believed were technically expert, had formed individual relationships with them, and respected them. They therefore valued forms of communication that are currently not emphasised in training and research and did not intrinsically value others that are currently thought important, including provision of information and choice. CONCLUSIONS: Women with breast cancer seek to regard their doctors

BMJ2004 Full Text: Link to full Text with Trip Pro

1870. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries.

Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries. BACKGROUND: The Collaborative Group on Hormonal Factors in Breast Cancer has brought together the worldwide epidemiological evidence on the possible relation between breast cancer and previous spontaneous and induced abortions. METHODS: Data on individual women from 53 studies undertaken in 16 countries with liberal abortion laws were checked (...) and analysed centrally. Relative risks of breast cancer--comparing the effects of having had a pregnancy that ended as an abortion with those of never having had that pregnancy--were calculated, stratified by study, age at diagnosis, parity, and age at first birth. Because the extent of under-reporting of past induced abortions might be influenced by whether or not women had been diagnosed with breast cancer, results of the studies--including a total of 44000 women with breast cancer--that used prospective

Lancet2004

1871. Caloric restriction and incidence of breast cancer.

Caloric restriction and incidence of breast cancer. CONTEXT: Restricting caloric intake is one of the most effective ways to extend lifespan and to reduce spontaneous tumor occurrence in experimental animals, but whether similar associations hold in humans has not been appropriately studied. OBJECTIVE: To determine whether caloric restriction in early life reduces the risk of invasive breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study using data from the Swedish (...) Inpatient Registry, the Swedish Cancer Registry, the Swedish Death Registry, and the Swedish Fertility Registry. Participants were 7303 Swedish women hospitalized for anorexia nervosa prior to age 40 years between 1965 and 1998. Women were excluded (n = 31) if they were diagnosed with cancer prior to their first discharge from hospitalization for anorexia nervosa. MAIN OUTCOME MEASURE: Incidence of invasive breast cancer. RESULTS: Compared with the Swedish general population, women hospitalized

JAMA2004

1872. Antibiotic use in relation to the risk of breast cancer.

Antibiotic use in relation to the risk of breast cancer. CONTEXT: Use of antibiotics may be associated with risk of breast cancer through effects on immune function, inflammation, and metabolism of estrogen and phytochemicals; however, clinical data on the association between antibiotic use and risk of breast cancer are sparse. OBJECTIVE: To examine the association between use of antibiotics and risk of breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Case-control study among 2266 women older (...) than 19 years with primary, invasive breast cancer (cases) enrolled in a large, nonprofit health plan for at least 1 year between January 1, 1993, and June 30, 2001, and 7953 randomly selected female health plan members (controls), frequency-matched to cases on age and length of enrollment. Cases were ascertained from the Surveillance, Epidemiology, and End Results cancer registry. Antibiotic use was ascertained from computerized pharmacy records. MAIN OUTCOME MEASURE: Association between extent

JAMA2004

1873. Effect of breast augmentation on the accuracy of mammography and cancer characteristics.

Effect of breast augmentation on the accuracy of mammography and cancer characteristics. CONTEXT: Breast augmentation is not associated with an increased risk of breast cancer; however, implants may interfere with the detection of breast cancer thereby delaying cancer diagnosis in women with augmentation. OBJECTIVE: To determine whether mammography accuracy and tumor characteristics are different for women with and without augmentation. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort (...) of 137 women with augmentation and 685 women without augmentation diagnosed with breast cancer between January 1, 1995, and October 15, 2002, matched (1:5) by age, race/ethnicity, previous mammography screening, and mammography registry, and 10 533 women with augmentation and 974 915 women without augmentation and without breast cancer among 7 mammography registries in Denver, Colo; Lebanon, NH; Albuquerque, NM; Chapel Hill, NC; San Francisco, Calif; Seattle, Wash; and Burlington, Vt. MAIN OUTCOME

JAMA2004

1874. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study.

Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. OBJECTIVE: To investigate whether information on mammographic screening presented on websites by interest groups is balanced, is independent of source of funding, and reflects recent findings. DESIGN: Cross sectional study using a checklist with 17 information items. SETTING: 27 websites in Scandinavian and English speaking countries. RESULTS: The 13 sites from advocacy groups

BMJ2004 Full Text: Link to full Text with Trip Pro

1875. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care National Institute for Clinical Excellence Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. London: National Institute for Clinical Excellence (NICE) 2004: 40 Authors' objectives This report provides guidelines on the classification and care of women at risk of familial breast cancer

Health Technology Assessment (HTA) Database.2004

1876. Computer aided detection of breast cancer

Computer aided detection of breast cancer Computer aided detection of breast cancer Computer aided detection of breast cancer Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement. Computer aided detection of breast cancer. Bloomington MN: Institute for Clinical Systems Improvement (...) (ICSI) 2004: 18 Authors' objectives This review aims to assess the available evidence on the computer aided detection of breast cancer in mammography images. Authors' conclusions With regard to computer aided detection (CAD) of breast cancer, the ICSI Technology Assessment Committee finds: CAD causes no direct harm to patients. Misdiagnoses (false-positive or false-negative results) can lead to unnecessary follow-up testing, unnecessary patient anxiety, or delays in obtaining treatment. Lower

Health Technology Assessment (HTA) Database.2004

1877. Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer

Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Kerr J Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kerr J. Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer. Christchurch: New Zealand Health Technology Assessment (NZHTA) 2004: 49 Authors' objectives To review the evidence for the effectiveness of infrared thermography for population screening and diagnostic testing of breast cancer. - Topic

Health Technology Assessment (HTA) Database.2004

1878. Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy

Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy Benk V, Fisher A, Glazer D, Paszat L Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Benk V, Fisher A, Glazer D, Paszat L. Impact of radiation wait times on risk of local recurrence of breast cancer: early stage cancer with no chemotherapy. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2004: 28 Authors' objectives The aim of this review was to assess the relationship between the risk of local recurrence (LR) of breast cancer and the waiting times

Health Technology Assessment (HTA) Database.2004

1879. Measuring the quality of breast cancer care in women

Measuring the quality of breast cancer care in women Measuring the quality of breast cancer care in women Measuring the quality of breast cancer care in women Moher D, Schachter HM, Mamaladze V, Lewin G, Paszat L, Verma S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Moher D, Schachter HM, Mamaladze V, Lewin G, Paszat L, Verma S (...) . Measuring the quality of breast cancer care in women. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 105. 2004 Authors' objectives The purpose of this systematic review of the scientific-medical literature was to survey the range of quality measures assessing the quality of breast cancer care in women, and to characterize specific parameters potentially affecting their suitability for wider use. Specific emphasis was placed on diagnosis, treatment

Health Technology Assessment (HTA) Database.2004

1880. Interstitial laser therapy for breast cancer

Interstitial laser therapy for breast cancer Interstitial laser therapy for breast cancer Interstitial laser therapy for breast cancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Interstitial laser therapy for breast cancer. London: National Institute for Clinical (...) Excellence (NICE) 2004: 2 Authors' objectives This study aims to assess the current evidence on the safety and efficacy of interstitial laser therapy for breast cancer. Authors' conclusions Guidance 1.1 Current evidence on the safety and efficacy of interstitial laser therapy for breast cancer does not appear adequate to support the routine use of this procedure. It is suitable for use only within good-quality research studies approved by a research ethics committee and with explicit patient consent. 1.2

Health Technology Assessment (HTA) Database.2004